A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)
NCT ID: NCT00735267
Last Updated: 2012-11-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
468 participants
INTERVENTIONAL
2008-10-31
2009-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PD 0332334
Dosage Form: 25 or 100 mg oral capsules Dosage and frequency: 350-600 mg twice a day Duration: 1 year
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Female must continue to use adequate birth control methods and have a negative serum pregnancy test within 14 days prior to starting open label treatment.
Exclusion Criteria
* Individuals who have an ongoing, unresolved, clinically significant medical problem that, in the judgment of the investigator or the sponsor's medical monitor, would make it unsafe for the subject to participate in the study.
* Serious suicidal risk per the clinical investigators's judgement.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pfizer, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Birmingham, Alabama, United States
Pfizer Investigational Site
Litchfield Park, Arizona, United States
Pfizer Investigational Site
Arcadia, California, United States
Pfizer Investigational Site
Beverly Hills, California, United States
Pfizer Investigational Site
Costa Mesa, California, United States
Pfizer Investigational Site
Costa Mesa, California, United States
Pfizer Investigational Site
Encino, California, United States
Pfizer Investigational Site
Escondido, California, United States
Pfizer Investigational Site
Murrieta, California, United States
Pfizer Investigational Site
National City, California, United States
Pfizer Investigational Site
Newport Beach, California, United States
Pfizer Investigational Site
Orange, California, United States
Pfizer Investigational Site
Pasadena, California, United States
Pfizer Investigational Site
Redlands, California, United States
Pfizer Investigational Site
San Diego, California, United States
Pfizer Investigational Site
San Diego, California, United States
Pfizer Investigational Site
Sherman Oaks, California, United States
Pfizer Investigational Site
Temecula, California, United States
Pfizer Investigational Site
Upland, California, United States
Pfizer Investigational Site
Wildomar, California, United States
Pfizer Investigational Site
Denver, Colorado, United States
Pfizer Investigational Site
Hamden, Connecticut, United States
Pfizer Investigational Site
Norwich, Connecticut, United States
Pfizer Investigational Site
Altamonte Springs, Florida, United States
Pfizer Investigational Site
Fort Myers, Florida, United States
Pfizer Investigational Site
Jacksonville, Florida, United States
Pfizer Investigational Site
Maitland, Florida, United States
Pfizer Investigational Site
Miami, Florida, United States
Pfizer Investigational Site
Miami, Florida, United States
Pfizer Investigational Site
Orange City, Florida, United States
Pfizer Investigational Site
Orlando, Florida, United States
Pfizer Investigational Site
South Miami, Florida, United States
Pfizer Investigational Site
West Palm Beach, Florida, United States
Pfizer Investigational Site
Atlanta, Georgia, United States
Pfizer Investigational Site
Atlanta, Georgia, United States
Pfizer Investigational Site
Marietta, Georgia, United States
Pfizer Investigational Site
Libertyville, Illinois, United States
Pfizer Investigational Site
Naperville, Illinois, United States
Pfizer Investigational Site
Park Ridge, Illinois, United States
Pfizer Investigational Site
Greenwood, Indiana, United States
Pfizer Investigational Site
Terre Haute, Indiana, United States
Pfizer Investigational Site
Overland Park, Kansas, United States
Pfizer Investigational Site
Prairie Village, Kansas, United States
Pfizer Investigational Site
Wichita, Kansas, United States
Pfizer Investigational Site
Owensboro, Kentucky, United States
Pfizer Investigational Site
Lake Charles, Louisiana, United States
Pfizer Investigational Site
Baltimore, Maryland, United States
Pfizer Investigational Site
Belmont, Massachusetts, United States
Pfizer Investigational Site
Boston, Massachusetts, United States
Pfizer Investigational Site
Fall River, Massachusetts, United States
Pfizer Investigational Site
Haverhill, Massachusetts, United States
Pfizer Investigational Site
Pittsfield, Massachusetts, United States
Pfizer Investigational Site
Omaha, Nebraska, United States
Pfizer Investigational Site
Las Vegas, Nevada, United States
Pfizer Investigational Site
Nashua, New Hampshire, United States
Pfizer Investigational Site
Albuquerque, New Mexico, United States
Pfizer Investigational Site
Brooklyn, New York, United States
Pfizer Investigational Site
New York, New York, United States
Pfizer Investigational Site
New York, New York, United States
Pfizer Investigational Site
New York, New York, United States
Pfizer Investigational Site
Rochester, New York, United States
Pfizer Investigational Site
The Bronx, New York, United States
Pfizer Investigational Site
Raleigh, North Carolina, United States
Pfizer Investigational Site
Columbus, Ohio, United States
Pfizer Investigational Site
Dayton, Ohio, United States
Pfizer Investigational Site
Toledo, Ohio, United States
Pfizer Investigational Site
Toledo, Ohio, United States
Pfizer Investigational Site
Bethany, Oklahoma, United States
Pfizer Investigational Site
Oklahoma City, Oklahoma, United States
Pfizer Investigational Site
Oklahoma City, Oklahoma, United States
Pfizer Investigational Site
Portland, Oregon, United States
Pfizer Investigational Site
Salem, Oregon, United States
Pfizer Investigational Site
Allentown, Pennsylvania, United States
Pfizer Investigational Site
Media, Pennsylvania, United States
Pfizer Investigational Site
Norristown, Pennsylvania, United States
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States
Pfizer Investigational Site
Lincoln, Rhode Island, United States
Pfizer Investigational Site
Columbia, South Carolina, United States
Pfizer Investigational Site
Memphis, Tennessee, United States
Pfizer Investigational Site
Memphis, Tennessee, United States
Pfizer Investigational Site
Austin, Texas, United States
Pfizer Investigational Site
Dallas, Texas, United States
Pfizer Investigational Site
Dallas, Texas, United States
Pfizer Investigational Site
DeSoto, Texas, United States
Pfizer Investigational Site
Houston, Texas, United States
Pfizer Investigational Site
Houston, Texas, United States
Pfizer Investigational Site
Lake Jackson, Texas, United States
Pfizer Investigational Site
San Antonio, Texas, United States
Pfizer Investigational Site
Woodstock, Vermont, United States
Pfizer Investigational Site
Charlottesville, Virginia, United States
Pfizer Investigational Site
Seattle, Washington, United States
Pfizer Investigational Site
Middleton, Wisconsin, United States
Pfizer Investigational Site
Waukesha, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A5361022
Identifier Type: -
Identifier Source: org_study_id